Theravance Biopharma announced a companywide wind‑down of research and development and a 50% workforce reduction after its lead candidate, ampreloxetine, failed a Phase 3 study in neurogenic orthostatic hypotension and a targeted subgroup analysis also missed endpoints. The company said the moves will reduce cash burn by roughly 60% and shift focus to commercial operations around its approved respiratory product, Yupelri. Management framed the changes as necessary to preserve cash and operational continuity while exploring strategic alternatives for remaining assets.